Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242460430> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4242460430 endingPage "4" @default.
- W4242460430 startingPage "1" @default.
- W4242460430 abstract "Objective: For 2019 and 2020, SARS-CoV-2 has been a sensational virus. Unfortunately, a treatment agent specific for SARS-CoV-2 has not been developed yet. Favipiravir is one of the antiviral agents used experimentally in the treatment of SARS-CoV-2. This study aimed to determine the frequency of side effects seen in patients hospitalized in our hospital and received favipiravir at any stage of their treatment. Methods: Our study is a retrospective observational study. Definite and probable COVID-19 cases hospitalized in our hospital between March 23, 2020, May 31, 2020, were determined, and those receiving favipiravir as initial or secondary therapy were included in the study. The demographic data, laboratory tests, observed side effects of the patients were recorded and analyzed statistically. Results: A total of 134 patients, 37.3% using favipiravir at the beginning and 62.7% as secondary, were included in the study. The mean age of the patients was 66.8±15.7 years. 38.1% (n=51) of the group were female. Side effects were detected in 17 (13%) patients in the whole group. Hepatotoxicity (4.5%), increased serum uric acid (4.5%), nephrotoxicity (1.5%), gastrointestinal side effects (1.5%), cardiac side effects (0.7%) were detected. There was no statistically significant difference in terms of adverse events between the patients who received favipiravir initially or later on disease course. Conclusions: Although some results support the short-term safety of favipiravir, more studies are needed for its long-term effects. Studies on hyperuricemia, QTc prolongation, use in pregnancy, use during lactation and use in children are insufficient. Therefore, although Favipiravir appears to be a good alternative in the treatment of COVID-19, it should be used carefully because the data on its safety is still insufficient." @default.
- W4242460430 created "2022-05-12" @default.
- W4242460430 creator A5003618040 @default.
- W4242460430 creator A5008030162 @default.
- W4242460430 creator A5025738741 @default.
- W4242460430 creator A5037740011 @default.
- W4242460430 creator A5037858197 @default.
- W4242460430 creator A5041035490 @default.
- W4242460430 creator A5041942835 @default.
- W4242460430 creator A5066153167 @default.
- W4242460430 date "2021-07-08" @default.
- W4242460430 modified "2023-10-14" @default.
- W4242460430 title "Investigation of the Frequency of Adverse Effects in Patients Treated with Favipiravir as SARS-CoV-2 Treatment" @default.
- W4242460430 doi "https://doi.org/10.36519/2021.3563" @default.
- W4242460430 hasPublicationYear "2021" @default.
- W4242460430 type Work @default.
- W4242460430 citedByCount "0" @default.
- W4242460430 crossrefType "journal-article" @default.
- W4242460430 hasAuthorship W4242460430A5003618040 @default.
- W4242460430 hasAuthorship W4242460430A5008030162 @default.
- W4242460430 hasAuthorship W4242460430A5025738741 @default.
- W4242460430 hasAuthorship W4242460430A5037740011 @default.
- W4242460430 hasAuthorship W4242460430A5037858197 @default.
- W4242460430 hasAuthorship W4242460430A5041035490 @default.
- W4242460430 hasAuthorship W4242460430A5041942835 @default.
- W4242460430 hasAuthorship W4242460430A5066153167 @default.
- W4242460430 hasBestOaLocation W42424604301 @default.
- W4242460430 hasConcept C126322002 @default.
- W4242460430 hasConcept C197934379 @default.
- W4242460430 hasConcept C199360897 @default.
- W4242460430 hasConcept C23131810 @default.
- W4242460430 hasConcept C2779134260 @default.
- W4242460430 hasConcept C2779772310 @default.
- W4242460430 hasConcept C3008058167 @default.
- W4242460430 hasConcept C3454156 @default.
- W4242460430 hasConcept C41008148 @default.
- W4242460430 hasConcept C524204448 @default.
- W4242460430 hasConcept C71924100 @default.
- W4242460430 hasConceptScore W4242460430C126322002 @default.
- W4242460430 hasConceptScore W4242460430C197934379 @default.
- W4242460430 hasConceptScore W4242460430C199360897 @default.
- W4242460430 hasConceptScore W4242460430C23131810 @default.
- W4242460430 hasConceptScore W4242460430C2779134260 @default.
- W4242460430 hasConceptScore W4242460430C2779772310 @default.
- W4242460430 hasConceptScore W4242460430C3008058167 @default.
- W4242460430 hasConceptScore W4242460430C3454156 @default.
- W4242460430 hasConceptScore W4242460430C41008148 @default.
- W4242460430 hasConceptScore W4242460430C524204448 @default.
- W4242460430 hasConceptScore W4242460430C71924100 @default.
- W4242460430 hasLocation W42424604301 @default.
- W4242460430 hasOpenAccess W4242460430 @default.
- W4242460430 hasPrimaryLocation W42424604301 @default.
- W4242460430 hasRelatedWork W2138843186 @default.
- W4242460430 hasRelatedWork W2765980456 @default.
- W4242460430 hasRelatedWork W2976382042 @default.
- W4242460430 hasRelatedWork W3092613758 @default.
- W4242460430 hasRelatedWork W3095488865 @default.
- W4242460430 hasRelatedWork W3174302937 @default.
- W4242460430 hasRelatedWork W3181290183 @default.
- W4242460430 hasRelatedWork W3217408445 @default.
- W4242460430 hasRelatedWork W4315781792 @default.
- W4242460430 hasRelatedWork W4383817509 @default.
- W4242460430 isParatext "false" @default.
- W4242460430 isRetracted "false" @default.
- W4242460430 workType "article" @default.